1988 Agent Summary Statement for Human Immunodeficiency Virus and Report on Laboratory-Acquired Infection with Human Immunodeficiency Virus [MMWR, Vol 37 No.S-4]

16

MMWR

April 1, 1988

ADDENDUM 2
CDC cautionary notice for all human-serum-derived reagents used as controls:
WARNING: Because no test method can offer complete assurance that
laboratory specimens do not contain HIV, hepatitis B virus, or other infectious agents, this specimen should be handled at the BSL 2 as recommended
for any potentially infectious human serum or blood specimen in the
CDC-NIH manual, Biosafety in Microbiological and Biomedical Laboratories,
1984, pages 11-13.
If additional statements describing the results of any heat treatment or serologic
procedure(s) already performed on the human-serum reagent or control are used in
conjunction with the above cautionary notice, these statements should be worded so
as not to diminish the impact of the warning that emphasizes the need for universal
precautions.
References
1. Richardson JH, Barkley WE, eds. Biosafety in microbiological and biomedical laboratories,
1984. Washington, DC: Public Health Service, 1984; DHHS publication no. (CDC)84-8395.
2. CDC. Human T-lymphotropic virus type III/lymphadenopathy-associated virus agent summary statement. MMWR 1986;35:540-2, 547-9.
3. CDC. Recommendations for prevention of HIV transmission in health-care settings. MMWR
1987;36(suppl 2):3S-18S.
4. Isenberg HD, Washington JA, Balows A, Sonnenwirth AC. Collection, handling and processing of specimens. In: Lennette EH, Balows A, Hausler WJ, Shadomy HJ, eds. Manual of
clinical microbiology, 4th ed. Washington, DC: American Society for Microbiology,
1985:73-98.
5. CDC. Acquired immune deficiency syndrome (AIDS): precautions for clinical and laboratory
workers. MMWR 1982;32:577-80.
6. CDC. Recommendations for preventing transmission of infection with human
T-lymphotropic virus type III/lymphadenopathy-associated virus in the workplace. MMWR
1985;34:681.
7. CDC. Recommendations for preventing transmission of infection with human
T-lymphotropic virus type III/lymphadenopathy-associated virus during invasive procedures. MMWR 1986;35:221-3.
8. CDC. Recommendations for preventing transmission of infection with human
T-lymphotropic virus type III/lymphadenopathy-associated virus in the workplace. MMWR
1985;34:682-6, 691-5.
9. U.S. Department of Health and Human Services, Public Health Service. Joint advisory
notice: HBV/HIV. Federal Register 1987;52 (October 30): 41818-24.
10. CDC. Update: evaluation of human T-lymphotropic virus type III/lymphadenopathyassociated virus infection in health-care personnel-United States. MMWR 1985;34:575-8.
11. CDC. Human immunodeficiency virus infections in health-care workers exposed to blood of
infected patients. MMWR 1987;36:285-9.
12. Anonymous. Needlestick transmission of HTLV-III from a patient infected in Africa. Lancet
1984;2:1376-7.
13. Stricof RL, Morse DL. HTLV-III/LAV seroconversion following a deep intramuscular needlestick injury. New EngI J Med 1986;314:1115.
14. McCray E, Cooperative Needlestick Study Group. Occupational risk of the acquired immunodeficiency syndrome among health-care workers. N EngI J Med 1986;314:1127-32.
15. Weiss SH, Saxinger WC, Richtman D, et al. HTLV-II infection among health-care workers:
association with needlestick injuries. JAMA 1985;254:2089-93.